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Abstract:
Background: Patients treated with chemotherapy for microsatellite-unstable (MSI) and/or mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) exhibit poor prognosis. We aimed to evaluate the relevance of distinguishing sporadic from Lynch syndrome (LS)-like mCRCs.
Patients and methods: MSI/dMMR mCRC patients were retrospectively identified in 6 French hospitals. Tumor samples were screened for MSI, dMMR, RAS/RAF mutations and MLH1 methylation. Sporadic cases were molecularly defined as those displaying MLH1/PMS2 loss of expression with BRAFV600E and/or MLH1 hypermethylation and no MMR germline mutation.
Results: Among 129 MSI/dMMR mCRC patients, 81 (63%) were LS-like and 48 (31%) had sporadic tumors; 22% of MLH1/PMS2-negative mCRCs would have been misclassified using an algorithm based on local medical records (age, Amsterdam II criteria, BRAF and MMR statuses when locally tested), compared to a systematical assessment of MMR, BRAF and MLH1 methylation statuses. In univariate analysis, parameters associated with better overall survival were age (P<.0001), metastatic resection (P=.001) and LS-like mCRC (P=.01), but not BRAFV600E. In multivariate analysis, age (hazard ratio (HR)=3. 19 , P=.01) and metastatic resection (HR=4.2, P=.001) were associated with overall survival, but not LS. LS-like patients were associated with more frequent liver involvement, metastatic resection and better disease-free survival after metastasectomy (HR=.28, P=.01). Median progression-free survival of first-line chemotherary was similar between the 2 groups (4.2 and 4.2 months; P=.44).
Conclusions: LS-like and sporadic MSI/dMMR mCRCs display distinct natural histories. MMR, BRAF mutation and MLH1 methylation testing should be mandatory to differentiate LS-like and sporadic MSI/dMMR mCRC, to determine in particular whether immune checkpoint inhibitors efficacy differs in these 2 populations.
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Highlights:
-Metastatic colorectal cancers with sporadic or inherited mismatch repair deficiency display distinct natural histories.
-A molecular algorithm combining MMR protein expression, BRAF mutation and MLH1 methylation testing is mandatory to properly determine the mechanism underlying mismatch repair deficiency.
-A better characterization of MSI/dMMR CRCs is needed to determine whether the effectiveness of therapeutic agents (chemotherapy, targeted therapies, immune checkpoint inhibitors) differs depending on the origin of the MMR deficiency.
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INTRODUCTION
Microsatellite instability (MSI) is caused by the deficiency of the mismatch repair (MMR) system, resulting from a germline mutation in MMR genes (MLH1, PMS2, MSH2, MSH6) predisposing to Lynch syndrome (LS), or an epigenetic inactivation of MLH1. Sporadic MSI/MMR-deficient (dMMR) colorectal cancer (CRC), unlike LS-related CRC, is associated with the BRAFV600E mutation, through its association with CIMP (CpG island methylator phenotype) [1] . MMR genes germline mutation cannot always be detected in LS and the definition of sporadic MSI/dMMR CRCs and CRCs presumed to be LS-related (i.e. Lynch-like) has evolved over time, from clinical criteria to a tailored approach with BRAF and MLH1 methylation testing for CRCs showing a loss of MLH1 expression [2] [3] [4] [5] .
Stage II MSI/dMMR CRC has a favorable prognosis. 5-fluorouracile-based adjuvant chemotherapy (5fluorouracile alone, with leucovorin or levamisol) is ineffective on stage II MSI/dMMR CRCs [6] .
However, the addition of oxaliplatine to fluoropyrimidines seems associated with a survival benefit for patients with high-risk stage II or stage III MSI/dMMR CRCs [7, 8] . Sensitivity to fluoropyrimidine may differ between sporadic and hereditary stage III MSI/dMMR CRCs [8, 9] . In metastatic setting, the poor prevalence of MSI/dMMR (3-5%) hampers the evaluation of its prognostic value, and results from early studies were inconsistent [10] [11] [12] [13] [14] . The pooled analysis of four phase III studies in first-line treatment of mCRC demonstrated that dMMR is associated with reduced progression-free survival (PFS) and overall survival (OS), with an insignificant negative effect of BRAFV600E among MSI mCRCs [15] . Thus, the impact of BRAFV600E on MSI CRCs remains controversial.
While immune checkpoint inhibitors (ICK) have demonstrated promising efficacy for MSI tumors, unresolved issues persist concerning molecular and clinical heterogeneity among MSI/dMMR mCRC patients [16, 17] . In our multicentre retrospective study, we aimed to evaluate a molecular definition of sporadic and inherited MMR deficiency of MSI/dMMR mCRC patients, with a particular interest in its clinical relevance before the era of immunotherapy.
MATERIAL AND METHODS

Study population
This retrospective study was conducted in 6 French hospitals. All patients with locally determined MSI and/or dMMR mCRC were eligible. Tumor specimen collection was mandatory. Exclusion MLH1/PMS2-negative tumors harboring BRAF mutation or MLH1 hypermethylation were considered sporadic [18] . Similarly, sporadic or hereditary origin of MSI tumors with no loss of MMR protein expression was determined according to BRAF mutation and MLH1 methylation [figure S1].
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As comparator, an unsystematic molecular definition that only takes into account data provided by local pathological and medical records was also used (i.e. MMR testing and BRAF status when available; if not, age inferior to 60 years or Amsterdam II criteria) [8, 9] .
Statistical analysis
Median value (interquartile range) and frequency (percentage) were provided for the description of continuous and categorical variables, respectively. Medians and proportions were compared according to hereditary or sporadic origin using Student's t test and chi-square test (or Fisher's exact test, if appropriate), respectively.
For patients with initially stage I-III tumors, disease-free survival (DFS) was calculated from primary tumor surgery to relapse (second CRC, loco-regional or metastatic relapse) or death. Overall survival (OS) was defined as the time between the diagnostic of metastatic disease to the date of death as a result of any cause. Patients treated with ICK in clinical trials were excluded from OS analysis. For patients with resected metastatic disease, DFS was calculated from the date of metastasis resection to the date of relapse or death. Progression-free survival (PFS) was calculated from the date of first-line chemotherapy initiation for metastatic disease to the date of tumor progression or death from any cause; patients with metastasectomy during chemotherapy course were excluded from PFS analysis.
Survival curves were estimated using the Kaplan-Meier method and compared with a Log-rank test.
Follow-up was calculated by reverse Kaplan-Meier estimation. .
Cox proportional hazard models were performed to estimate hazard ratio (HR) and 95% confidence interval (95%CI) for factors associated with OS. The association of baseline parameters with OS was first assessed using univariate Cox analyses, parameters with P values < .05 were then entered into a final multivariate Cox regression model after considering collinearity among variables with a correlation matrix.
All analyses were performed using SAS version 9.4 (SAS Institute, Cary NC) and R software version 2.15.2 (R Development Core Team, Vienna, Austria; http://www.r-project. org). P values of less than .05 were considered statistically significant, and all tests were two-sided.
RESULTS
Population
Among 160 patients identified with dMMR and/or MSI mCRC, 31 were excluded: no tumor sample available (N = 15), pMMR and MSS tumors according to centrally analysis (N = 16). The 129 remaining patients had been diagnosed with mCRC between January 1998 and January 2016.
Distinction between sporadic and Lynch-like tumors
Results of MMR immunohistochemistry, BRAF mutation and MLH1 methylation analysis are presented in table 1. Forty-eight patients (37%) had sporadic dMMR/MSI mCRC and 81 (63%) were presumed to be Lynch-like, according to the molecular approach combining MMR, MLH1 methylation and BRAF mutation testing. Of note, 18 out of all 48 sporadic MSI/dMMR mCRCs (38%) were BRAF wild-type but MLH1 hypermethylated.
A MMR gene germline mutation was known for 34 patients (26%). No BRAF mutation or MLH1 hypermethylation were detected in the tumors of these 34 Lynch syndrome-proven patients.
22% of MLH1 and/or PMS2 negative mCRCs with no known MMR germline mutation (14/64) would have been misclassified using an unsystematic molecular approach. Taking into account local pathological records only, in the absence of our systematic analysis of BRAF mutation and MLH1 methylation, 9 Lynch-like tumors would have been considered as sporadic and 5 sporadic MSI/dMMR mCRCs as Lynch-like [table S1].
Clinical and molecular characteristics
Demographic and clinical characteristics are summarized in table 2. Median age at diagnosis of mCRC was 57 years. Among initially localized MSI/dMMR mCRCs (N = 69), 33% were stage II and 67% stage III. Main first metastatic sites were: peritoneum (46%), liver (38%), distant lymph nodes (33%) and lung (2%).
Patients with sporadic MSI/dMMR mCRC were associated with female (P < 0.001), older age at diagnosis (P < 0.0001), right-sided primary tumor (P = 0.02) and less liver involvement (P = 0.02), with a trend for synchronous metastatic disease (56% versus 41%, P = 0.10). A sex ratio of 3.1 (male/female) was observed for patients with Lynch-like mCRC.
Thirty-three per cent, 3% and 23% of all MSI/dMMR mCRCs harbored a mutation of KRAS, NRAS and BRAF, respectively. Forty-five tumors (35%) were all wild-type. (table S2) .
Resection of metastatic disease
Among patients with sporadic MSI/dMMR mCRC, no difference in OS was observed according to BRAF status (P = 0.91).
Disease-free survival
For patients with initially localized mCRC (N = 69), median DFS was 11.63 months in the overall population, 9.8 months for sporadic cases and 12.1 months for Lynch-like tumors (HR = 0.53, 95%CI
[0.74-2.1], P = .04).
For patients with metastatic disease resection (N = 54), median DFS after metastasectomy was 9.5 months and was significantly inferior for sporadic than Lynch-like patients (6.7 versus 10.5 months, HR = 0.28, 95%CI [0.1-0.73], P = 0.01) [ figure 1 ].
First-line progression-free survival
Sixty-three patients received first-line chemotherapy for unresectable metastatic disease. Median PFS were associated with chemotherapy for 24 (38%) and 12 (19%) patients, respectively.
DISCUSSION
We report here a large cohort dedicated to patients with MSI/dMMR mCRC. Although retrospective, this multicenter study exhibits robustness thanks to the mandatory tumor specimen collection. This biological collection paired to a clinical database allowed a systematic analysis of microsatellite, MMR, BRAF and MLH1 methylation statuses [16] [15][16] [16] .
We show that the determination of MMR deficiency origin using a molecular approach is technically feasible in metastatic setting and efficient, despite poor pre-analysis conditions (i.e. retrospectively collected FFPE samples). Indeed, 22% of patients with MLH1/PMS2-negative mCRC would have been misclassified using widely-used algorithms combining MMR immunohistochemistry, BRAF mutation, age and Amsterdam II criteria [8, 9] . Notably, 38% of sporadic MSI/dMMR mCRCs were BRAF wild-type but MLH1 hypermethylated. Twenty-five per cent of patients with sporadic MSI/dMMR mCRC were aged 60 or less, and 25% of Lynch-like patients were older than 55 years, indicating that age is ineffective at distinguishing inherited and sporadic MSI/dMMR mCRCs. Thus, when the germline MMR gene mutation analysis is not available, it is necessary to test MMR protein expression using immunohistochemistry and, for MLH1/PMS2-negative tumors, both BRAF mutation and MLH1 methylation, in order to correctly identify sporadic or Lynch-like MSI/dMMR mCRCs [18, 19] .
In our cohort, 62% of MSI/dMMR mCRCs were presumed to be related to Lynch syndrome. This result might be explained by the fact that many participants of this cohort are expert centers for familial colorectal cancers. However, the true proportion of sporadic and inherited tumors among MSI/dMMR mCRCs is unknown. In our study, patients with sporadic MSI/dMMR mCRC were associated with female, older age, right-sided primary tumor and less liver involvement. These results are concordant with previously published works [12, 20] . Surprisingly, Lynch-like mCRC patients had a sex ratio superior to 3 in favor of male. This trend was observed in a pooled analysis of randomized trials in first-line treatment among BRAF wild-type dMMR mCRC patients (66 males, 33 females) [15] . Further research will have to explore the biological determinants of this finding.
The inherited origin of MMR deficiency, younger age at diagnosis of mCRC and resection of metastasis were associated with better OS in univariate analysis. Our study being insufficiently powered to compute age as a continuous variable in multivariate analysis, a cut-off of 70 years was used [21] . Younger age and metastatic surgery, but not LS, were associated with OS in multivariate analysis. However collinearity among these variables was observed.
Of note, BRAFV600E was not associated with OS. Moreover, no prognostic difference was observed between BRAF-mutated and -wild type sporadic MSI/dMMR mCRC. This enlightens the analysis of Venderbosch and colleagues where the negative prognostic effect of BRAFV600E on OS did not reach statistical significance within MSI/dMMR mCRCs (HR = 1.51, 95%CI 0.93-2.46) [15] . On the contrary, Goldstein et al. reported a statistically significant negative impact of BRAFV600E on OS in a retrospective cohort of 55 MSI/dMMR mCRCs [22] . In localized setting, BRAFV600E is not associated with prognosis (OS) among stage II and III MSI/dMMR CRCs [21, 23] . Since CMS 1 (consensus molecular subtype 1) has high BRAF-mutated and MSI tumors and is characterized by favorable recurrence-free survival but poor survival after relapse, it appears necessary to investigate the clinical and molecular heterogeneity of CMS1 CRCs, with a particular interest in CIMP status, which overlaps with BRAF mutation and MSI phenotype [24, 25] .
Patients with Lynch-like mCRC underwent metastasis surgery more frequently and exhibited a significantly better median DFS than sporadic MSI/dMMR mCRC patients (HR = 0.28, 95%CI [0.1-0.73], P = 0.01). This might be explained by the fact that Lynch-like mCRCs are associated with younger age and higher frequency of liver metastasis. Moreover, MMR genes mutation carriers are followed with colonoscopy every 1 to 2 years, allowing the early detection of CRC, whereas patients with sporadic MSI/dMMR mCRCs are associated with older age and therefore frequently out of screening programs [19, 26] .
Median PFS for patients receiving first-line chemotherapy for unresectable mCRC did not differ between sporadic and Lynch-like groups (4.2 months in both groups). This is consistent with the analysis of Venderbosch and colleagues (median PFS of 6.1 and 6.3 months for BRAF-mutated and BRAF-wild type MSI mCRC patients, respectively) [15] . The poor median PFS in first-line setting with comparison to the analysis of Venderbosch might be partly explained by the retrospective nature of our study. Moreover, since it was retrospectively not possible to properly differentiate patients with resectable or unresectable metastatic disease before the initiation of first-line chemotherapy, we excluded patients with metastasectomy from this PFS analysis.
Nivolumab monotherapy for MSI/dMMR mCRC (N = 74) showed promising efficacy in patients with or without clinical history of LS, determined by investigators based on past medical history collected from clinical records [17] . Similarly, favorable outcomes have been reported among BRAFV600Emutated MSI/dMMR mCRCs treated with ICK [16, 17, 27] . However, these results should be taken with caution as the criteria for the distinction between sporadic and LS-related MMR deficiency were unclear. Given the clinical and survival differences observed in our cohort between sporadic and LSrelated MSI/dMMR mCRC patients, the mechanism of the MMR deficiency should be systematically determined in future studies evaluating therapies in this population. An efficient and consensual definition, as we propose here, will be necessary to properly evaluate the efficacy of ICK for patients with MSI/dMMR mCRC with regards on the mechanism underlying MMR deficiency.
CONCLUSION
As immunotherapy is on the rise for MSI/dMMR tumors, there is an urge for studies that clinically and molecularly characterize patients with MSI/dMMR mCRCs before the era of ICK. We show that MMR protein expression, BRAF mutation and MLH1 promoter methylation testing are needed to properly distinguish sporadic and inherited MSI/dMMR mCRCs. MSI/dMMR mCRC is a clinically heterogeneous disease associated with poor chemosensitivity. With a distinct pattern of metastatic spread characterized by a higher frequency of liver involvement, patients with Lynch-like mCRC are associated with younger age, more frequent metastatic surgery and favorable prognosis compared to those with sporadic MSI/dMMR mCRC. BRAF mutation, MLH1 methylation and MMR testing will be essential to evaluate whether the efficacy of anticancer treatments differs between sporadic and LSrelated MSI/dMMR mCRC patients. Loss of expression of MSH6 alone 9 (7) -9
Loss of expression of PMS2 alone 5 (4) Applied Biosystems, Foster City, California, USA).We did not analyzed samples for NRAS exon 4 mutations given their very low frequency in metastatic CRC [1] . Values in brackets correspond to percentages relative to patients with a loss of MLH1 and/or PMS2 expression in the tumor and no known MMR gene germline mutation (N = 64) * Tumors with BRAFV600E mutation and/or hypermethylated MLH1 promoter were considered sporadic; BRAF wild-type tumors with no hypermethylation of MLH1 promoter were suspected to be related to Lynch syndrome ** All patients were considered to have sporadic dMMR CRC, except patients with a loss of MSH2/MSH6 expression, or a loss of MLH1 without BRAFV600E mutation and age inferior to 60 years, or if they met the Amsterdam II criteria in the absence of MMR immunochemistry [8] . 
